EUCTR2020-005493-10-IT招募中1 期
Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML) that is Refractory to or Relapsed after Induction Therapy - na
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 63
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. The subject has a pathologically confirmed diagnosis of AML by World Health Organization classification. This must be in the form of either a bone marrow aspirate or biopsy or a CBC that demonstrates >5% myeloblasts.
- •2. The subject has AML that is refractory to or relapsed after induction therapy. To be defined as relapse, there must be >5% blasts in the bone marrow.
- •3. For the expansion phase only (i.e., after the MTD/RP2D is established), subjects must be treated with L-Annamycin as second- or third-line therapy (i.e., subjects could not have received more than one prior therapy for their relapsed/refractory AML).
- •4. The subject is age =18 years at the time of signing informed consent.
- •5. The subject has received no chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of study drug and/or has recovered from the toxic side effects of that therapy unless treatment is indicated as a result of progressive disease, such as hydroxyurea.
- •6. The subject has received no investigational therapy within 4 weeks of the first dose of study drug.
- •7. The subject has an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
- •8. The subject has a HCT-CI score (Sorror index) 0-2
- •9. The subject has adequate laboratory results including the following:
- •a. Bilirubin =2 times the upper limit of normal unless due to Gilbert Syndrome or leukemic infiltration of the liver.
- •b. Serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT), and alkaline phosphatase <2.5 times the upper limit of normal unless due to organ involvement.
- •c. Adequate renal function with creatinine levels =2 times the upper limit of normal.
- •10. The subject can understand and sign the informed consent document, can communicate with the Investigator, and can understand and comply with the requirements of the protocol.
- •11. Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin test within 72 hours prior to first dose of study drug to rule out pregnancy.
- •12. All men and women must agree to practice effective contraception during the entire study period and after discontinuing study drug, unless documentation of infertility exists.
- •a. Sexually active, fertile women must use 2 effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from the time of informed consent until at least 6 months after discontinuing study drug.
- •b. Sexually active men and their sexual partners must use effective contraceptive methods from the time of subject informed consent until at least 3 months after discontinuing study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 23
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1. The subject was diagnosed with acute promyelocytic leukemia.
- •2. The subject is receiving concomitant therapy that includes other chemotherapy that is or may be active against AML except for agents such as hydroxyurea, just to control the WBC count until chemotherapy or prophylaxis and/or treatment of opportunistic or other infection with antibiotics, antifungals, and/or antiviral agents, including therapy for meningeal disease (i.e., intrathecal chemotherapy), supportive measures,and medications as per standard of care up to Day 1 of L-Annamycin administration.
- •3. The subject received prior mediastinal radiotherapy.
- •4. The subject has central nervous system involvement.
- •5. The subject has any condition that, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study.
- •6. The subject has an LVEF <50%, valvular heart disease, or severe hypertension. Cardiac subjects with a New York Heart Association classification of 3 or 4 will be excluded. (Cardiology consultation should be requested if any question arises about cardiac function). This also includes subjects with baseline QT/QTc interval >480 msec, a history of additional risk factors for torsade des pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome), and use of concomitant medications that significantly prolong the QT/QTc interval.
- •7. The subject has clinically relevant serious comorbid medical conditions including, but not limited to, active infection, recent (less than or equal to 6 months) myocardial infarction, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, known positive status for human immunodeficiency virus and/or active hepatitis B or C, cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements.
- •8. The subject is pregnant, lactating, or not using adequate contraception.
- •9. The subject has a known allergy to anthracyclines and/or hypersensitivity to cytarabine, or excipients.
- •10. The subject has any evidence of mucositis/stomatitis at the time of study entry or previous history of severe (=Grade 3) mucositis from prior therapy.
- •11. The subject is required to use moderate or strong inhibitors and inducers of Cytochrome P450 family of enzymes (CYP) and transporters that cannot be held for 3 days prior to Day 1 and during treatment days.
研究者
相似试验
招募中
2 期
A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin administered with cytarabine, in patients with acute myeloid leukemia.Acute Myeloid Leukemia2024-516388-10-00Moleculin Biotech Inc.24
进行中（未招募）
1 期
A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin, in patients with acute myeloid leukemia, refractory in which the disease has not responded to treatments or relapsed, where the disease came back after previous treatment.Acute Myeloid LeukemiaMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2017-003969-10-PLMoleculin Biotech, Inc.75
招募中
1 期
Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary MetastasesSoft Tissue SarcomaPulmonary MetastasisNCT05518526Maria Sklodowska-Curie National Research Institute of Oncology64
已完成
1 期
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)Leukemia, Myeloid, AcuteNCT05319587Moleculin Biotech, Inc.22
已完成
1 期
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary MetastasesSarcoma,Soft TissuePulmonary MetastasisNCT04887298Moleculin Biotech, Inc.36